Specialty focus enables UCB to repel austerity
This article was originally published in Scrip
By focusing on specialty drugs for severe neurological and immunology disorders UCB CEO Roch Doliveux believes his company is positioned well to cope with payer pressures in the developed world while making major headway in key emerging markets. Indeed, in his last year at the helm, Mr Doliveux is expecting UCB to deliver double digit EBITDA and EPS growth in 2014.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.